Caricamento...
A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas: A Study of the Mayo Phase 2 Consortium (P2C)
BACKGROUND: The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI-779), a mammalian target of rapamycin in patients with advanced soft tissue sarcomas (STS). METHODS: Patients ≥18 years with measurable advanced STS, no prior chemotherapy for metastatic disea...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2011
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3312920/ https://ncbi.nlm.nih.gov/pubmed/21287536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25928 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|